Business Context and Reporting Period
This Form 8-K was filed by Inotek Pharmaceuticals Corporation on September 28, 2016. The report discloses the appointment of a new director to the Board of Directors. Note: The request metadata lists "Rocket Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Inotek Pharmaceuticals Corporation.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Stock Option Grant: 24,000 shares of common stock.
- Exercise Price: $9.49 per share (equal to fair market value on the grant date).
- Vesting Schedule: 25% vests on the one-year anniversary; the remainder vests monthly (1/36th) thereafter, contingent on continued service.
Material Changes
The material change reported is the election of Timothy J. Barberich as a Class III independent director. He was also appointed as the Chairperson of the Compensation Committee. No material changes to financial operations or corporate structure beyond this personnel change are reported.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this report, other than the standard vesting conditions tied to the director's continued service.
Investor Verification Checklist
- Verify the correct registrant name (Inotek Pharmaceuticals Corporation vs. Rocket Pharmaceuticals, Inc.).
- Confirm the independence status of the new director under NASDAQ Listing Rules.
- Review the press release (Exhibit 99.1) for additional context on the appointment.
- Check subsequent filings for the impact of the new director on board committee composition.